The company said revenue for Q2 (ended June 29, 2024) declined to $10.54 billion from $10.69 billion a year earlier, down 1%. GAAP diluted EPS rose 15% to $4.04, and adjusted EPS rose 4% to $5.37.

1. 01

   The company said revenue for Q2 (ended June 29, 2024) declined to $10.54 billion from $10.69 billion a year earlier, down 1%. GAAP diluted EPS rose 15% to $4.04, and adjusted EPS rose 4% to $5.37.

2. 02

   The company said GAAP operating income for Q2 rose to $1.82 billion (operating margin of 17.3%) from $1.58 billion (14.8%) a year earlier. Adjusted operating income was $2.35 billion (22.3%), compared with $2.37 billion (22.2%) a year earlier.

3. 03

   Thermo Fisher generated operating cash flow of $1,960 million and free cash flow (non-GAAP) of $1,674 million in Q2, compared with $1,260 million a year earlier. Free cash flow for the 6 months to date was $2,583 million, and share repurchases over the same period totaled $3,000 million.

4. 04

   The company said it is raising its full-year revenue outlook to $42.4 to $43.3 billion from $42.3 to $43.3 billion, and its adjusted EPS outlook to $21.29 to $22.07 from $21.14 to $22.02. It also said it completed its acquisition of Olink shortly after the quarter ended.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.